Deferasirox in children with transfusion-dependent thalassemia or sickle cell anemia: A large cohort real-life experience from Turkey (REACH-THEM).
Ali Bülent AntmenZeynep KarakaşMehmet Akif YeşilipekOsman Alphan Küpesizİlgen ŞaşmazVedat UygunErdal KurtoğluGonul OktayGonul AydoganMehmet AkınZafer SalciogluCanan VerginElif Güler KazancıSelma ÜnalÜmran ÇalışkanYusuf Ziya AralEmine TürkkanAdalet Meral GüneşBahattin TunçFatma GümrükAylin Canbolat AyhanMurat SökerAhmet KoçYeşim OymakMehmet ErtemÇetin TimurYıldız YıldırmakGülersu İrkenHilmi ApakBetül BinerTuğba Gürleyen ErenYasemin Işık BalcıÜlker KoçakGülsün KarasuDiyar AkkaynakTürkan PatıroğluPublished in: European journal of haematology (2018)
Deferasirox has long-term efficacy and safety in children with TDT and SCA, although higher doses (≥30 mg/kg/d) may be required to achieve iron balance.